Skip to main content
Premium Trial:

Request an Annual Quote

Orchid s 39-Percent Revenue Increase Leads to Narrowed Q3 Losses

NEW YORK, Oct. 26 (GenomeWeb News) - Orchid Biosciences reported an increase in revenues and narrowed losses in the third quarter, resulting in the first quarterly operating profit in the company's history, Orchid said today.


Orchid's revenues increased by 39 percent, to $16.4 million in Q3 2004, from $11.8 million for the year-ago period. Revenue growth was driven by increases in the company's forensics and scrapie susceptibility testing volumes, Qiagen said.


Orchid's net loss for the third quarter was $0.4 million, an improvement from $5.0 million for the third quarter last year. Orchid posted operating income of $176,000 and income of $383,000 from continuing operations before income taxes for the third quarter this year, marking the first quarterly operating profit in the company's history, it said.


As of Sept. 30, 2004, Orchid had $30.5 million in cash, cash equivalents, and short-term investments, of which $24.6 million were in cash and cash equivalents.


Separately, Orchid announced today that it has been selected by the Thames Valley Police as its exclusive provider of forensic DNA testing services.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.